Autolus Therapeutics plc
AUTL
$1.60
$0.021.27%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/10/2026
-
Insider Monkey
5/7/2026
-
MarketBeat
5/5/2026
-
Globe Newswire
5/4/2026
-
MarketBeat
5/1/2026
-
Insider Monkey
4/30/2026
-
Insider Monkey
4/29/2026
-
TipRanks Financial Blog
4/29/2026
-
Globe Newswire
4/23/2026
-
MarketBeat
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
4/22/2026
-
Globe Newswire
4/21/2026
-
Globe Newswire
4/21/2026
-
MarketBeat
4/13/2026
-
MarketBeat
4/13/2026
-
TipRanks Financial Blog
4/13/2026
-
TipRanks Financial Blog
4/13/2026
-
MarketBeat
4/9/2026
-
MarketBeat
4/8/2026
-
SeekingAlpha
4/8/2026
-
Seeking Alpha: Transcripts
4/8/2026
-
SeekingAlpha
4/8/2026
-
TipRanks Financial Blog
4/8/2026
-
MarketBeat
4/7/2026
-
Globe Newswire
4/4/2026
-
Insider Monkey
4/4/2026
-
Yahoo! Finance: News
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, March 27, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
44 20 3829 6230
Address
The Mediaworks
191 Wood Lane - White City
London, W12 7FP
191 Wood Lane - White City
London, W12 7FP
Country
Year Founded
Business Description
Sector
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The...
more